July 6, 2020 / 11:22 AM / a month ago

BRIEF-Emergent Biosolutions Says Will Begin Providing Large-Scale Drug Substance Manufacturing For Johnson & Johnson's Adenovirus-Based Covid-19 Vaccine In 2021

July 6 (Reuters) - Emergent BioSolutions Inc:

* EMERGENT BIOSOLUTIONS SIGNS FIVE-YEAR AGREEMENT FOR LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S LEAD COVID-19 VACCINE CANDIDATE

* EMERGENT BIOSOLUTIONS- WILL BEGIN PROVIDING LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S ADENOVIRUS-BASED COVID-19 VACCINE IN 2021

* EMERGENT BIOSOLUTIONS INC - WILL PROVIDE AN UPDATE TO ITS 2020 FINANCIAL OUTLOOK INCORPORATING EXPECTATIONS RELATED TO AGREEMENT

* EMERGENT - WILL PROVIDE SERVICES PRODUCE DRUG SUBSTANCE AT LARGE SCALE FOR COMMERCIAL MANUFACTURING WITH FIRST 2 YEARS VALUED AT ABOUT $480 MILLION

* EMERGENT BIOSOLUTIONS -FOR REMAINING 3 YEARS BEGINNING IN 2023, CO WILL PROVIDE FLEXIBLE CAPACITY DEPLOYMENT MODEL TO SUPPORT ANNUAL DOSE REQUIREMENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below